An ISCOM vaccine combined with a TLR9 agonist breaks immune evasion mediated by regulatory T cells in an orthotopic model of pancreatic carcinoma.

@article{Jacobs2011AnIV,
  title={An ISCOM vaccine combined with a TLR9 agonist breaks immune evasion mediated by regulatory T cells in an orthotopic model of pancreatic carcinoma.},
  author={Collin Jacobs and Peter Duewell and Klaus Heckelsmiller and Jiwu Wei and Franz Bauernfeind and Jonathan Ellermeier and Ulrich Kisser and Christian A. J. Schulze – Bauer and Marc Dauer and Andreas Eigler and Eugene Maraskovsky and Stefan C. Endres and Max Schnurr},
  journal={International journal of cancer},
  year={2011},
  volume={128 4},
  pages={897-907}
}
Vaccines based on immune stimulatory complexes (ISCOM) induce T-cell responses against tumor antigen (Ag). However, immune responses are impaired in pancreatic cancer patients. We investigated the efficacy of an ISCOM vaccine in a murine pancreatic carcinoma model. Panc02 cells expressing OVA as a model Ag were induced subcutaneously or orthotopically in the pancreas of C57BL/6 mice. Treatment consisted of an OVA containing ISCOM vaccine, either used alone or in combination with the TLR9… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 43 extracted citations

Similar Papers

Loading similar papers…